Bachelor in Chemistry at the Universidade Estadual de Campinas (1982) and a PhD in Biochemistry at the Universidade de São Paulo (1988). Has experience in Molecular Biotechnology, working in the following subjects: Vaccine development, recombinant BCG, pertussis, pneumococcus, tuberculosis and schistosoma. She is researcher at the Butantan Institute's Vaccine Development Laboratory (formerly Biotechnology Center). Has experience in Molecular Biotechnology, focusing on Vaccine Development, acting on the following subjects: recombinant BCG vaccines, pertussis, pneumococcus, tuberculosis and schistosoma. She has been Vice Director of Fundação Butantan (2005-2009), Director of the Center of Biotechnology (2010-2016) and of the Laboratory of Vaccine Development of Instituto Butantan (2016-2019) and Member of the Steering Committee of the Developing Countries Vaccine Manufacturing Network (DCVMN) (2006-2014), Comissão Técnica Nacional de Biossegurança (CTNBio) (2013-2019) and Comissão de Ética em Pesquisa com Seres Humanos do ICB -USP (2020-2023). Currently is member of the Academic Management Board of the LIVE-Leading International Vaccinology Education Course of Erasmus / European Union (2016- ), the Coalition for Epidemic Preparedness and Innovation (CEPI -2024- ) and RedeTB (Brazilian TB Network). (Source: Lattes Curriculum)
| Articles published in Pesquisa para Inovação FAPESP about the researcher: |
| FAPESP-funded startups are developing COVID-19 vaccines |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Our studies have demonstrated the advantages of Mycobacterium bovis BCG as an antigen presenting system in the development of new vaccines. The project aims to expand the use of methods of heterologous gene expression in BCG developed in our laboratories with the aim of proposing new vaccines in the immunization against Pertussis, Tuberculosis, Pneumococcus and Schistosome, and to improve…
Vaccination is one of the greatest triumphs of modern medicine, yet we remain largely ignorant of the mechanisms by which successful vaccines stimulate protective immunity. The grand challenge for biology and medicine at the turn of the 21st century is to understand the biological complexity that emerges from interactions between our immune system and the environment (e.g. pathogens). To …
(Only some records are available in English at this moment)
Cancer treatment has always been a challenge, as local and systemic tumor factors create a complex microenvironment that generates a set of signals impacting infiltrating immune cells. For instance, peripheral blood monocytes from cancer patients tend to transform into immunosuppressive antigen-presenting cells (APCs), where soluble factors "educate" immune cells not to activate efficient…
Bacillus of Calmette and Guérin (BCG) is a live attenuated vaccine of the pathogenic strain Mycobacterium bovis. Its emergence occurred from subsequent cultures of the strain in a medium containing bovine bile, which resulted, empirically, in the attenuation of virulence and pathogenicity in animal models. In the following years, BCG became widely used, being the only vaccine against tube…
The vaccines currently in use against the SARS-CoV-2 coronavirus were developed based on both traditional processes and more modern technologies such as viral vectors and RNA-based vaccines. These new strategies were very effective and safe in clinical trials and have shown great efficiency in the control of COVID-19. These approaches take into account the presentation of important antige…
The COVID-19 pandemic is responsible for causing the greatest crisis of the last century. Mass vaccination is considered the most effective option for stopping the virus. The long-term effects of COVID-19 on the immune response are still being studied and will be crucial in determining which vaccine strategy is best suited to maintain long-term immunity. Furthermore, the emergence of vari…
The recent worldwide SARS-CoV-2 Coronavirus epidemic calls for coordinated efforts by the scientific community to develop new diagnostic tests, new treatments and the development of vaccines. The effort to develop vaccines has focused on modifications of technologies that were already under development for other similar viruses, such as the SARS-CoV-1 Coronavirus, MERS, and even Influenza…
(Only some records are available in English at this moment)
Tuberculosis (TB) is a global health burden. Besides the public health issue, the disease is also an economic problem in livestock production. Vaccination is the most cost effective strategy for TB control. So far, the only licensed vaccine is BCG, a live attenuated strain of Mycobacterium bovis. Although it carries several advantages, BCG protection declines over time, ranging from 0-80%…
Tuberculosis (TB) was responsible for more than 10.4 million cases and 1.8 million deaths in 2015. This is primarily because the only available vaccine, BCG, fails to reduce TB incidence sufficiently, there is a lack of biomarkers of protection and of biomarkers predicting treatment outcome, and there is a rising frequency of multi drug-resistant (MDR) Mycobacterium tuberculosis (Mtb) str…
| 1 / 1 | Ongoing grants |
| 12 / 10 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 52 / 22 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 70 / 38 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID